152 related articles for article (PubMed ID: 38369783)
1. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
[TBL] [Abstract][Full Text] [Related]
2. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
3. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
4. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
6. Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Massoth LR; Hung YP; Nardi V; Nielsen GP; Hasserjian RP; Louissaint A; Fisch AS; Deshpande V; Zukerberg LR; Lennerz JK; Selig M; Glomski K; Patel PJ; Williams KJ; Sokol ES; Alexander BM; Vergilio JA; Ross JS; Pavlick DC; Chebib I; Williams EA
Mod Pathol; 2020 Nov; 33(11):2307-2317. PubMed ID: 32461620
[TBL] [Abstract][Full Text] [Related]
7. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
[TBL] [Abstract][Full Text] [Related]
9. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma.
Mentzel T; Brown LF; Dvorak HF; Kuhnen C; Stiller KJ; Katenkamp D; Fletcher CD
Virchows Arch; 2001 Jan; 438(1):13-22. PubMed ID: 11213831
[TBL] [Abstract][Full Text] [Related]
10. Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.
Kao YC; Ranucci V; Zhang L; Sung YS; Athanasian EA; Swanson D; Dickson BC; Antonescu CR
Am J Surg Pathol; 2017 Nov; 41(11):1456-1465. PubMed ID: 28692601
[TBL] [Abstract][Full Text] [Related]
11. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
[TBL] [Abstract][Full Text] [Related]
12. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract][Full Text] [Related]
13. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
Zheng B; Qu Y; Wang J; Shi Y; Yan W
Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
[TBL] [Abstract][Full Text] [Related]
16. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases.
Nascimento AF; Bertoni F; Fletcher CD
Am J Surg Pathol; 2007 Jan; 31(1):99-105. PubMed ID: 17197925
[TBL] [Abstract][Full Text] [Related]
17. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
[TBL] [Abstract][Full Text] [Related]
18. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.
Pestana RC; Roszik J; Groisberg R; Sen S; Van Tine BA; Conley AP; Subbiah V
Curr Probl Cancer; 2021 Oct; 45(5):100794. PubMed ID: 34656365
[TBL] [Abstract][Full Text] [Related]
19. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
[TBL] [Abstract][Full Text] [Related]
20. Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.
Heitzer E; Sunitsch S; Gilg MM; Lohberger B; Rinner B; Kashofer K; Stündl N; Ulz P; Szkandera J; Leithner A; Liegl-Atzwanger B
Mod Pathol; 2017 Dec; 30(12):1698-1709. PubMed ID: 28776571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]